Pertussis Vaccines

Global Pertussis Vaccines Market to Reach US$8.3 Billion by 2030

The global market for Pertussis Vaccines estimated at US$6.4 Billion in the year 2024, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. DTaP Vaccine, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Tdap Vaccine segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 8.3% CAGR

The Pertussis Vaccines market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Pertussis Vaccines Market – Key Trends & Drivers Summarized

Why Is Pertussis Vaccination Regaining Urgency in Global Immunization Strategies?

Pertussis, commonly known as whooping cough, remains a significant public health threat despite decades of immunization programs. Caused by Bordetella pertussis, the disease poses severe risks to infants and immunocompromised individuals, often leading to hospitalization or fatal respiratory complications. The resurgence of pertussis in both high- and low-income countries is driving renewed focus on vaccine coverage, booster programs, and maternal immunization strategies.

The evolving epidemiology of pertussis—marked by increased incidence among adolescents and adults—has prompted healthcare agencies to revise immunization schedules. Recommendations now include adolescent boosters (Tdap), cocooning strategies for caregivers, and immunization during pregnancy to confer passive immunity to neonates. These policy shifts are supporting demand for both whole-cell (wP) and acellular (aP) pertussis vaccines, each with differing profiles of efficacy, reactogenicity, and public acceptance.

How Are Innovation and Reformulation Efforts Addressing Waning Immunity and Outbreak Management?

A major challenge in pertussis control is the waning immunity associated with acellular vaccines, which, although safer than whole-cell counterparts, provide shorter duration of protection. This has led to outbreaks even in highly vaccinated populations. Researchers and manufacturers are actively working on next-generation pertussis vaccines with improved adjuvants, extended immunogenicity, and broader strain coverage.

Novel formulations under development include live attenuated nasal vaccines, genetically detoxified pertussis toxins, and nanoparticle-based adjuvants aimed at enhancing mucosal immunity. These innovations are intended to strengthen herd immunity, especially in populations with high transmission potential such as school-aged children and healthcare workers. Additionally, advancements in combination vaccines (e.g., DTaP, Tdap-IPV-HepB-Hib) are streamlining immunization logistics and improving compliance in pediatric and adult populations.

Why Are Global Health Initiatives, Supply Chain Enhancements, and Policy Frameworks Vital to Market Expansion?

Global vaccination efforts led by organizations such as Gavi, WHO, and UNICEF continue to play a pivotal role in expanding pertussis vaccine access in low- and middle-income countries. These agencies support procurement, distribution, and cold-chain management while also funding education campaigns to reduce vaccine hesitancy. Public-private partnerships are further aiding vaccine affordability and localized production through technology transfers and licensing agreements.

Policy frameworks are also evolving to incorporate pertussis surveillance into national disease monitoring systems. Integrated immunization schedules, digital tracking tools, and catch-up campaigns are being implemented to address immunity gaps. Countries are increasingly prioritizing pertussis control within maternal and child health programs, boosting both demand and funding for vaccines. These systemic developments are improving market predictability and encouraging long-term investment by biopharmaceutical companies.

What’s Driving the Continued Growth of the Pertussis Vaccines Market Globally?

The growth in the pertussis vaccines market is driven by several factors including rising disease incidence, expansion of maternal immunization programs, and technological innovations in vaccine development. A key growth driver is the shift toward booster-based lifelong immunization strategies that extend coverage beyond infancy and target adolescents, adults, and seniors.

Moreover, the rising awareness of pertussis complications, improvements in diagnostic surveillance, and increased integration with combination vaccine platforms are further strengthening market momentum. As countries scale up efforts to meet global immunization targets and mitigate preventable deaths, pertussis vaccines remain central to national and international public health agendas.

With the ongoing emergence of pertussis variants, increasing healthcare investments in immunization infrastructure, and strong demand for safer, more effective vaccine formulations, the pertussis vaccines market is positioned for sustained global growth in both public health and private clinical sectors.

SCOPE OF STUDY:

The report analyzes the Pertussis Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (DTaP Vaccine, Tdap Vaccine); End-Use (Vaccination Centers, Hospitals, Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Astellas Pharma Inc.
• Bharat Biotech International Limited
• Biological E. Limited
• BioNet-Asia Co., Ltd.
• Cadila Healthcare Ltd. (Zydus Cadila)
• Chiron Behring Vaccines Pvt. Ltd.
• CSL Limited (Seqirus)
• GlaxoSmithKline plc
• Green Cross Corporation
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• ILiAD Biotechnologies, LLC
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanta Biotechnics Pvt. Ltd.
• Sinovac Biotech Ltd.
• Wuhan Institute of Biological Products Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.